Who we are

As a leading global clinical-stage biopharmaceutical company, we strive to create transformative medicines to protect and improve people’s lives. Fueled by our proprietary RNA technology platform combined with two decades of science and manufacturing excellence, we are dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.


For those interested to participate in the Phase 2b/3 clinical trial of ourCOVID-19 vaccine candidate CVnCoV (HERALD)

E-Mail